<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893486</url>
  </required_header>
  <id_info>
    <org_study_id>PALV-04</org_study_id>
    <nct_id>NCT04893486</nct_id>
  </id_info>
  <brief_title>CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome</brief_title>
  <official_title>A Multicenter, Phase 2B, Randomized, Double-Blind, Stratified, Vehicle-Controlled Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel In Prevention Of BCCs In Patients With Gorlin Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palvella Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Palvella Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2b study looks at the safety and efficacy of a treatment that is being investigated&#xD;
      for people with certain diseases. This study will be conducted at multiple centers in the&#xD;
      United States where participants with Gorlin Syndrome, also known as basal cell nevus&#xD;
      syndrome, will be randomly placed into two groups; one group will receive the active topical&#xD;
      gel, the other a topical vehicle gel, also know as placebo. Participants will apply this&#xD;
      topical product to their face once a day for 6 months. The study will be looking at the&#xD;
      number of new BCCs that develop on the faces of all the participants during this time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of new biopsy confirmed BCCs that develop on the face compared between the active and vehicle treatment arms</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dermatological, treatment emergent adverse events after treatment with active</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants developing 2 or more new biopsy confirmed BCCs on the face.</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants developing 1 or more new biopsy confirmed BCCs on the face.</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>BCCs in Gorlin Syndrome Patients</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTX-022</intervention_name>
    <description>QTORIN 3.9 % Sirolimus Topical Gel</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle comparator</intervention_name>
    <description>Vehicle comparator topical gel</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Adults, 18 years or older&#xD;
&#xD;
          -  Live in the United States&#xD;
&#xD;
          -  Meet diagnostic criteria for Gorlin Syndrome&#xD;
&#xD;
          -  Willing to avoid application of a non-study topical medication to the face&#xD;
             (prescription or over the counter) during the study.&#xD;
&#xD;
          -  Willing to forego treatment of BCCs with anything other than the study medication&#xD;
             except when the Investigator believes that delay of treatment of a BCC potentially&#xD;
             might compromise the health of the subject. During the trial, the only allowed form of&#xD;
             BCC treatment is surgical.&#xD;
&#xD;
          -  Participant will be encouraged to use their preferred sunscreen with a sun protector&#xD;
             factor (SPF) of at least 30 daily&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Recently participated in a clinical trial evaluating an investigational product for&#xD;
             the treatment of BCCs or Gorlin Syndrome within 3 months prior to to starting study&#xD;
             medication. Participant can start the study screening period prior to completing the 3&#xD;
             month washout.&#xD;
&#xD;
          -  Recently used topical or systemic (oral) treatment that might interfere with the&#xD;
             evaluation of the study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Bickers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joyce Teng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathy Goin</last_name>
    <phone>484-612-2335</phone>
    <email>kathy.goin@palvellatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Burke Pharmaceuticals Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Dugan</last_name>
      <phone>501-620-4449</phone>
      <email>tdugan@burkepharmaceutical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Park Avenue Dermatology</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dea Kemlage</last_name>
      <phone>904-458-0411</phone>
      <email>dkemlage@parkavedermatology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ameriderm Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gwinett Clinical Research Center</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Coordinating Center (Minnesota)</name>
      <address>
        <city>New Brighton</city>
        <state>Minnesota</state>
        <zip>55112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patient Navigator</last_name>
      <phone>763-571-4200</phone>
      <email>Gorlin.Codytrial@associatedskincare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rhonda Lebbing</last_name>
      <phone>314-977-1794</phone>
      <email>Rhonda.Lebbing@health.slu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DermResearch Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina Garcia</last_name>
      <phone>(512) 349-9889 x105</phone>
      <email>karina@driresearchsite.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sean Wetland</last_name>
      <phone>801-213-3427</phone>
      <email>sean.wentland@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Rivera</last_name>
      <phone>757-625-0151</phone>
      <email>erivera@vcrinc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salford Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://gorlinsyndrome.org/</url>
    <description>Gorlin Syndrome Alliance</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gorlin Syndrome</keyword>
  <keyword>Basal Cell Carcinoma</keyword>
  <keyword>Nevoid basal cell carcinoma syndrome</keyword>
  <keyword>Basal cell nevus syndrome BCNS</keyword>
  <keyword>Gorlin Syndrome Alliance</keyword>
  <keyword>Prevention</keyword>
  <keyword>Topical</keyword>
  <keyword>Sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Basal Cell Nevus Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

